Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Colombo

Showing results (181-190 of 219) with videos related to

Pageof 22
Sort By:
Lancet (London, England)|June 27, 2003
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialM K B Parmar, J A Ledermann, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerI Vergote, A González-Martín, I Ray-Coquard, et al.
ESMO Open|August 30, 2024
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasmsC Valenza, M Mongillo, F Gigli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalS B Kaye, N Colombo, B J Monk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2012
The need for accredited training in gynaecological oncology: a report from the European Network of Young Gynaecological Oncologists (ENYGO)R Manchanda, M Godfrey, L A Wong-Taylor, et al.
Bone Marrow Transplantation|October 14, 2014
DLI after haploidentical BMT with post-transplant CYA Ghiso, A M Raiola, F Gualandi, et al.
Bone Marrow Transplantation|June 4, 2015
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an updateA Bacigalupo, A Dominietto, A Ghiso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 3, 2009
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative StudyA A Lissoni, N Colombo, A Pellegrino, et al.
Gynecologic Oncology|January 22, 2022
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysisA Poveda, S Lheureux, N Colombo, et al.
Pageof 22

Showing results (181-190 of 219) with videos related to

Sort By:
Pageof 22
Lancet (London, England)|June 27, 2003
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialM K B Parmar, J A Ledermann, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerI Vergote, A González-Martín, I Ray-Coquard, et al.
ESMO Open|August 30, 2024
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasmsC Valenza, M Mongillo, F Gigli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free intervalS B Kaye, N Colombo, B J Monk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2012
The need for accredited training in gynaecological oncology: a report from the European Network of Young Gynaecological Oncologists (ENYGO)R Manchanda, M Godfrey, L A Wong-Taylor, et al.
Bone Marrow Transplantation|October 14, 2014
DLI after haploidentical BMT with post-transplant CYA Ghiso, A M Raiola, F Gualandi, et al.
Bone Marrow Transplantation|June 4, 2015
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an updateA Bacigalupo, A Dominietto, A Ghiso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 3, 2009
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative StudyA A Lissoni, N Colombo, A Pellegrino, et al.
Gynecologic Oncology|January 22, 2022
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysisA Poveda, S Lheureux, N Colombo, et al.
Pageof 22